EP2961483A4 - Verfahren und zusammensetzungen zur verbesserung einer immunreaktion, zur blockierung einer monozytenmigration, zur verstärkung einer impfstoffimmunität und zur hemmung von tumorwachstum und -metastasen - Google Patents

Verfahren und zusammensetzungen zur verbesserung einer immunreaktion, zur blockierung einer monozytenmigration, zur verstärkung einer impfstoffimmunität und zur hemmung von tumorwachstum und -metastasen Download PDF

Info

Publication number
EP2961483A4
EP2961483A4 EP14756530.3A EP14756530A EP2961483A4 EP 2961483 A4 EP2961483 A4 EP 2961483A4 EP 14756530 A EP14756530 A EP 14756530A EP 2961483 A4 EP2961483 A4 EP 2961483A4
Authority
EP
European Patent Office
Prior art keywords
metastasis
enhancing
compositions
methods
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14756530.3A
Other languages
English (en)
French (fr)
Other versions
EP2961483A2 (de
Inventor
Steven W. Dow
Daniel P. REGAN
Amanda M. GUTH
Leah Mitchell
Michelina PETRI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colorado State University Research Foundation
Original Assignee
Colorado State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorado State University Research Foundation filed Critical Colorado State University Research Foundation
Publication of EP2961483A2 publication Critical patent/EP2961483A2/de
Publication of EP2961483A4 publication Critical patent/EP2961483A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14756530.3A 2013-03-01 2014-03-03 Verfahren und zusammensetzungen zur verbesserung einer immunreaktion, zur blockierung einer monozytenmigration, zur verstärkung einer impfstoffimmunität und zur hemmung von tumorwachstum und -metastasen Withdrawn EP2961483A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361771738P 2013-03-01 2013-03-01
US201361771744P 2013-03-01 2013-03-01
US201361807189P 2013-04-01 2013-04-01
US201361818176P 2013-05-01 2013-05-01
PCT/US2014/020018 WO2014134621A2 (en) 2013-03-01 2014-03-03 Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis

Publications (2)

Publication Number Publication Date
EP2961483A2 EP2961483A2 (de) 2016-01-06
EP2961483A4 true EP2961483A4 (de) 2017-03-08

Family

ID=51428966

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14756530.3A Withdrawn EP2961483A4 (de) 2013-03-01 2014-03-03 Verfahren und zusammensetzungen zur verbesserung einer immunreaktion, zur blockierung einer monozytenmigration, zur verstärkung einer impfstoffimmunität und zur hemmung von tumorwachstum und -metastasen

Country Status (2)

Country Link
EP (1) EP2961483A4 (de)
WO (1) WO2014134621A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116299A2 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2016161309A1 (en) 2015-04-01 2016-10-06 Colorado State University Research Foundation Optimized cancer stem cell vaccines
WO2020028007A1 (en) * 2018-07-31 2020-02-06 Colorado State University Research Foundation Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
WO2012068531A2 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877067A1 (de) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-on-glucuronid-derivate gegen hypercholesterinämie
WO2011053789A2 (en) * 2009-10-30 2011-05-05 James Cameron Oliver Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
WO2012030234A1 (en) * 2010-09-01 2012-03-08 Swee Thong Tan Methods and compositions for treating cancer
AU2012206945B2 (en) * 2011-01-11 2015-02-19 Dimerix Bioscience Pty Ltd Combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
WO2012068531A2 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKIKO MIYAZAKI ET AL: "Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY ; INCORPORATING GERMAN JOURNAL OF OPHTHALMOLOGY, SPRINGER, BERLIN, DE, vol. 246, no. 5, 18 December 2007 (2007-12-18), pages 747 - 757, XP019629681, ISSN: 1435-702X *
KAYO SAGAWA ET AL: "Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice", ARTHRITIS & RHEUMATISM, vol. 52, no. 6, 1 June 2005 (2005-06-01), pages 1920 - 1928, XP055156348, ISSN: 0004-3591, DOI: 10.1002/art.21040 *
MAEDA A ET AL: "Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 10, 1 September 2009 (2009-09-01), pages 1183 - 1188, XP026502010, ISSN: 1567-5769, [retrieved on 20090621], DOI: 10.1016/J.INTIMP.2009.06.006 *
MICHIO KOSUGI ET AL: "Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer", HUMAN CELL, vol. 20, no. 1, 1 February 2007 (2007-02-01), UK; JP, pages 1 - 9, XP055290297, ISSN: 0914-7470, DOI: 10.1111/j.1749-0774.2007.00025.x *
NOGUCHI R ET AL: "Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 22, no. 2, 1 August 2009 (2009-08-01), pages 355 - 360, XP002744523, ISSN: 1021-335X, [retrieved on 20090801], DOI: 10.3892/OR_00000445 *

Also Published As

Publication number Publication date
EP2961483A2 (de) 2016-01-06
WO2014134621A2 (en) 2014-09-04
WO2014134621A3 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
HK1224334A1 (zh) 誘導抗腫瘤免疫力的化合物及其用途
EP3076994A4 (de) Gerichtete adaptive impfstoffe
EP3145842A4 (de) Lückenbildungssysteme und -verfahren
EP3092828A4 (de) Reiseumfragesysteme und verfahren
EP3005607A4 (de) Adaptive authentifizierungssysteme und -verfahren
EP2999471A4 (de) Vernetzungssysteme, -verfahren und -zusammensetzungen
GB201607957D0 (en) Methods and systems for acidizing subteranean formations
HK1226299A1 (zh) 用於誘發免疫反應的組合物、方法及工具
EP3288538A4 (de) Verfahren zur verstärkung einer immunreaktion anhand von depot-formenden und nicht-depot-formenden impfstoffen
EP3200831A4 (de) Impfstoffe mit einem antigen und interleukin-21 als adjuvans
EP3134104A4 (de) Synthetische haptenträgerzusammensetzungen und verfahren
EP3010340A4 (de) Zusammensetzungen und verfahren zur verstärkung einer immunantwort, zur immuntherapieverbesserung und zur erhöhung der potenz von impfstoffen
IL247614B (en) Methods and preparations for changing the immune response
EP2962113A4 (de) Systeme und verfahren mit anti-pd40-antikörpern
EP3052522A4 (de) Anti-sox10-antikörpersysteme und verfahren
EP3518976A4 (de) Zusammensetzungen und verfahren zur verbesserung der immunsystemfunktion
EP3086360A4 (de) Halbleiterbauelement, verfahren zur herstellung davon und aliphatisches polycarbonat
EP2961483A4 (de) Verfahren und zusammensetzungen zur verbesserung einer immunreaktion, zur blockierung einer monozytenmigration, zur verstärkung einer impfstoffimmunität und zur hemmung von tumorwachstum und -metastasen
EP2968843A4 (de) Absaugkatheter, -systeme und -verfahren
EP3074039A4 (de) Zusammensetzungen und verfahren zur modulierung einer immunreaktion
EP3191129A4 (de) Abzielung auf k-ras-vermittelte signalwege und malignome durch anti-hlif-antikörper
EP3238219A4 (de) Magnetische vorrichtungen mit geringem übersprechen
EP3393456A4 (de) Gegen immunzellen gerichtete partikel
EP3370826A4 (de) Verfahren zur behandlung von krebs durch erhöhung der intratumoralen immunreaktion
IL266750A (en) Methods of enhancing immune response with everolimus, dactolisib or both

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/41 20060101ALI20160921BHEP

Ipc: A61K 31/404 20060101ALI20160921BHEP

Ipc: A61K 31/537 20060101ALI20160921BHEP

Ipc: A61K 31/437 20060101ALI20160921BHEP

Ipc: A61P 31/12 20060101AFI20160921BHEP

Ipc: A61K 31/505 20060101ALI20160921BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170206

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/537 20060101ALI20170131BHEP

Ipc: A61K 31/41 20060101ALI20170131BHEP

Ipc: A61P 31/12 20060101AFI20170131BHEP

Ipc: A61K 31/404 20060101ALI20170131BHEP

Ipc: A61K 31/437 20060101ALI20170131BHEP

Ipc: A61K 31/505 20060101ALI20170131BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101ALI20170207BHEP

Ipc: A61K 31/505 20060101ALI20170207BHEP

Ipc: A61K 31/41 20060101ALI20170207BHEP

Ipc: A61K 31/404 20060101ALI20170207BHEP

Ipc: A61K 31/537 20060101ALI20170207BHEP

Ipc: A61P 31/12 20060101AFI20170207BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101ALI20170218BHEP

Ipc: A61K 31/505 20060101ALI20170218BHEP

Ipc: A61P 31/12 20060101AFI20170218BHEP

Ipc: A61K 31/404 20060101ALI20170218BHEP

Ipc: A61K 31/41 20060101ALI20170218BHEP

Ipc: A61K 31/537 20060101ALI20170218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170906